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anglais
Objective
Signs and symptoms of Cushing's disease are associated with high burden of
illness. In this analysis, we evaluated the effect of pasireotide treatment on signs
and symptoms in patients with Cushing's disease.
Design
Phase III study with double-blind randomization of two pasireotide doses.
Methods
Patients (n = 162) with persistent/recurrent or de novo Cushing's disease and
urinary free cortisol (UFC) levels ≥1·5× upper limit of normal (ULN) were
randomized to receive subcutaneous pasireotide (600/900 μg bid). At month 3,
patients with UFC ≤2 × ULN and not exceeding the baseline value continued their
randomized dose; all others received 300 μg bid uptitration. At month 6, patients
could enter an open-label phase until month 12 with a maximal dose of 1200 μg
bid. Changes in signs and symptoms of hypercortisolism over 12 months' treatment
in patients still enroled in the study and with evaluable measurements were
assessed in relation to degree of UFC control.
Results
Reductions in blood pressure were observed even without full UFC control and
were greatest in patients who did not receive antihypertensive medications during
the study. Significant reductions in total cholesterol and low-density lipoprotein
(LDL)-cholesterol were observed in patients who achieved UFC control. Reductions
in BMI, weight and waist circumference occurred during the study even without
full UFC control. Adverse effects were typical of somatostatin analogues except for
hyperglycaemia-related events, which were experienced by 72·8% of patients.
Conclusions
In the largest Phase III study of medical therapy in Cushing's disease, significant
improvements in signs and symptoms were seen during 12 months of pasireotide
treatment, as UFC levels decreased.
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